RevMan: review – intervention; 286625072323291815 (version 3.3)

Status: UNPUBLISHED DRAFT

Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency

Table of contents

Editors: Cochrane Gynaecology and Fertility Group

Corresponding author: Laurentiu Craciunas (lcraciunas@doctors.org.uk)

Newcastle Fertility Centre
Times Square
International Centre for Life
Newcastle upon Tyne
NE1 4EP
UK

Laurentiu Craciunas [1]Nikolaos Zdoukopoulos [2]Suganthi Vinayagam [3]Lamiya Mohiyiddeen [4]

[1] Newcastle Fertility Centre, Newcastle upon Tyne, UK

[2] Women's health unit, Royal Victoria Infirmary, Newcastle upon Tyne, UK

[3] Obstetrics and Gynaecology, St Helens and Knowsley Teaching Hospitals NHS Trust, Prescot, UK

[4] St Mary's Hospital, Manchester, UK

Citation

Craciunas L, Zdoukopoulos N, Vinayagam S, Mohiyiddeen L. Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency. Cochrane Database of Systematic Reviews TBD, Issue TBD. Art. No.: CD008209. DOI: 10.1002/14651858.CD008209.pub2.

Dates

Revision published: Issue TBD, TBD (TBD)

Version published (citation changed): Issue TBD, TBD (TBD)

Review first published: Issue TBD, TBD

Protocol first published: Issue 1, 2010

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size	
1.1 Uterine volume (mL)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only	
1.1.1 Measured at baseline	1	12	Mean Difference (IV, Fixed, 95% CI)	-0.30 [-1.88, 1.28]	
1.1.2 Measured after 12 months	1	12	Mean Difference (IV, Fixed, 95% CI)	-18.20 [-23.18, -13.22]	

History

Protocol first published: Issue 1, 2010

Sources of support

Internal sources

- No sources of support provided

External sources

- No sources of support provided

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Cleemann 2020

Study characteristics		
Methods		
Participants		
Interventions		
Outcomes		
Notes		
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	study identified as RCT, but no details for randomisation provided
Allocation concealment (selection bias)	Unclear risk	no allocation concealment details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	no blinding details provided, but unlikely to influence the outcome
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	no blinding details provided
Incomplete outcome data (attrition bias) All outcomes	High risk	4 participants from the high dose group did not complete the study period
Selective reporting (reporting bias)	Low risk	reported on relevant outcomes for the study question according to registry entry
Other bias	Low risk	no other sources of bias identified

Feng 2021

Study characteristics		
Methods		
Participants		
Interventions		
Outcomes		
Notes		
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	study identified as RCT, but no details for randomisation provided
Allocation concealment (selection bias)	Unclear risk	no allocation concealment details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	no blinding details reported, but unlikely to affect outcomes
Blinding of outcome assessment (detection bias) All outcomes	Low risk	ultrasound examiners blinded to treatment groups
Incomplete outcome data (attrition bias) All outcomes	Low risk	all participants accounted for
Selective reporting (reporting bias)	Low risk	reported on relevant outcomes for the study question according to registry entry
Other bias	Low risk	no other sources of bias identified

Nabhan 2009

Study characteristics		
Methods		
Participants		
Interventions		
Outcomes		
Notes		
Risk of bias		
Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Low risk	randomisation was computer generated and stratified by bone age
Allocation concealment (selection bias)	Unclear risk	no allocation concealment details provided
Blinding of participants and personnel (performance bias) All outcomes	Low risk	no blinding details reported, but unlikely to affect outcomes
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	no blinding details reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	all participants accounted for
Selective reporting (reporting bias)	Low risk	reported on relevant outcomes for the study question
Other bias	Low risk	no other sources of bias identified

References

References to studies included in this review

Cleemann 2020 {published data only}

Feng 2021 {published data only}

Nabhan 2009 {published data only}

Analysis 1.1

Study or Subgroup	Conjugated oral Mean	SD	Total	Transdermal Mean	SD	Total	Weight	Mean Difference IV, Fixed, 95% CI
1.1.1 Measured at baseline								
Nabhan 2009	1.6	1	6	1.9	1.7	6	100.0%	-0.30 [-1.88 , 1.28]
Subtotal			**6**			**6**	**100.0%**	**-0.30 [-1.88 , 1.28]**
Test for overall effect: Z = 0.37 (P = 0.71)								
Heterogeneity: Not applicable								
1.1.2 Measured after 12 months								
Nabhan 2009	4	4.4	6	22.2	4.4	6	100.0%	-18.20 [-23.18 , -13.22]
Subtotal			**6**			**6**	**100.0%**	**-18.20 [-23.18 , -13.22]**
Test for overall effect: Z = 7.16 (P < 0.00001)								
Heterogeneity: Not applicable								



Comparison 1: Conjugated oral oestrogens versus transdermal 17ß-estradiol, Outcome 1: Uterine volume (mL)